Mark Rothera

Directeur Général chez VIRACTA THERAPEUTICS, INC.

Profil

Mark A. Rothera is currently Chief Executive Officer at Viracta Therapeutics, Inc., Chief Executive Officer & Director at TreeFrog Therapeutics SAS starting in 2025, Director at Genpharm Services, and President & Director at Orchard Therapeutics North America.
Former roles include President, CEO & Executive Director at Silence Therapeutics Plc from 2020 to 2022; President, Chief Executive Officer & Director at Orchard Therapeutics (Europe) Ltd. from 2017 to 2020; President, CEO & Executive Director at Orchard Therapeutics Plc from 2018 to 2020; Director at Alliance for Regenerative Medicine; Director at INVO Fertility, Inc.; Chief Commercial Officer at PTC Therapeutics, Inc. from 2013 to 2017; Executive VP-Strategy & Business Development at Aegerion Pharmaceuticals, Inc. from 2012 to 2013; President & General Manager-Commercial Operations at Shire Human Genetic Therapies, Inc. from 2006 to 2012; and Vice President-Europe, Middle East & Africa at CHIRON Biopharmaceuticals from 2000 to 2005.
Education includes graduate studies at the University of Cambridge and an MBA from INSEAD.

Postes actifs de Mark Rothera

Sociétés	Poste	Début
VIRACTA THERAPEUTICS, INC.	Directeur Général	-
Genpharm Services	Directeur/Membre du Conseil	-
Orchard Therapeutics North America	President	-
TreeFrog Therapeutics SAS	Directeur Général	15/12/2025

Anciens postes connus de Mark Rothera

Sociétés	Poste	Fin
SILENCE THERAPEUTICS PLC	Directeur Général	21/02/2022
Orchard Therapeutics (Europe) Ltd.	Directeur Général	17/03/2020
ORCHARD THERAPEUTICS PLC	Directeur Général	17/03/2020
PTC THERAPEUTICS, INC.	Corporate Officer/Principal	09/08/2017
AEGERION PHARMACEUTICALS, INC.	Corporate Officer/Principal	01/01/2013